Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard.

Electroluminescent assays for epitopes on the complement components C3dg, terminal complement complex (TCC) and factor B/Bb (fB/Bb) have been developed with capture and detection antibodies to produce detection limits C3dg=91±9ng/mL, TCC=3±0.1ng/mL and fB=55.7±0.1ng/mL. The assay performance was assessed against a series of zymosan and heat aggregated IgG (HAIgG) in vitro activations of complement using a calibrated activated complement serum (ACS) as calibration standard. The ACS standard was stable within 20% accuracy over a 6-month period with freeze-thaw cycles as required. Differential activation of the complement cascade was observed for TCC showing a pseudo-first order formation half-life of 3.5h after activation with zymosan. The C3dg activation fragment indicates a 10% total activation for both activation agents. The kinetic-epitope analysis for fB indicates that the capture epitope is on the fB/Bb protein fragment which can then become covered by the formation of C3bBb or C3bBbP complexes during the time course of the cascade.

[1]  G. Kuchel,et al.  ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[2]  C. Vedeler,et al.  Systemic complement activation following human acute ischaemic stroke , 2004, Clinical and experimental immunology.

[3]  Z. Prohászka,et al.  Activation of the complement system in normal pregnancy and preeclampsia. , 2010, Molecular immunology.

[4]  I. Brewis The human plasma proteome , 2006 .

[5]  Bo Nilsson,et al.  An international serum standard for application in assays to detect human complement activation products. , 2013, Molecular immunology.

[6]  T. Hugli,et al.  Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. , 1999, Clinical chemistry.

[7]  O. Attrée,et al.  Comparison of electrochemiluminescence assay and ELISA for the detection of Clostridium botulinum type B neurotoxin. , 2005, Journal of immunological methods.

[8]  Bo Nilsson,et al.  Complement analysis in the 21st century. , 2007, Molecular immunology.

[9]  C. Hack,et al.  Complement activation in patients with sepsis is in part mediated by C-reactive protein. , 1998, The Journal of infectious diseases.

[10]  M. Oppermann,et al.  Complement activation in septic baboons detected by neoepitope‐specific assays for C3b/iC3b/C3c, C5a and the terminal C5b‐9 complement complex (TCC) , 1993, Clinical and experimental immunology.

[11]  L. Truedsson,et al.  Complement deficiencies and systemic lupus erythematosus , 2007, Autoimmunity.

[12]  S. Frøland,et al.  Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.

[13]  E. Brown,et al.  Complement activation. , 1981, Immunology today.

[14]  J. G. van der Hoeven,et al.  The complement system is activated in a biphasic pattern after coronary artery bypass grafting. , 2010, The Annals of thoracic surgery.

[15]  W. van Oeveren,et al.  Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. , 1999, Chest.

[16]  J. Köhl,et al.  Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. , 1995, Journal of immunological methods.

[17]  N. Hotta,et al.  Complement activation products in the urine from proteinuric patients. , 1998, Journal of the American Society of Nephrology : JASN.

[18]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[19]  J. Tschopp,et al.  A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9. , 1987, Journal of immunological methods.

[20]  G. Schoenhals,et al.  The human plasma proteome: A biomarker pool too deep to explore? , 2006 .

[21]  A. Familian,et al.  Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. , 2001, Arthritis and rheumatism.

[22]  M. Harboe,et al.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation , 2004, Clinical and experimental immunology.

[23]  R. Schreiber,et al.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[24]  O. Mellbye,et al.  Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. , 1986, Arthritis and rheumatism.

[25]  M. Walport,et al.  The Complement Factsbook , 1999 .

[26]  P. Thullier,et al.  Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). , 2007, Journal of immunological methods.

[27]  J. Tschopp,et al.  Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Tschopp,et al.  Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.

[29]  S. Sereika,et al.  Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. , 1996, Arthritis and rheumatism.

[30]  W. P. Reed,et al.  Classical and alternative complement pathway activation by pneumococci , 1977, Infection and immunity.

[31]  S. Abramson,et al.  Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. , 1986, Arthritis and rheumatism.